Boston Scientific's (BSX) NIR Stent Found Not to Infringe on J&J's (JNJ) Fischell Patent
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Join SI Premium – FREE
Boston Scientific Corporation (NYSE: BSX) reports the U.S. Court of Appeals for the Federal Circuit found in favor of the Company in a 1998 patent infringement suit involving Johnson & Johnson (NYSE: JNJ).
In today's decision, the Court of Appeals affirmed the U.S. District Court for the District of Delaware decision finding that Boston Scientific's NIR Stent did not infringe Johnson & Johnson's Fischell patent.
In today's decision, the Court of Appeals affirmed the U.S. District Court for the District of Delaware decision finding that Boston Scientific's NIR Stent did not infringe Johnson & Johnson's Fischell patent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Holcim to acquire Fermacell from James Hardie for EUR 840M
- Roots Corporation to go private in C$4.10-per-share deal with Marquee Brands
Create E-mail Alert Related Categories
Corporate News, FDA, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
